The effect of montelukast sodiumr on serum MMP-9 and TIMP-1 levels in acute exacerbations of chronic obstructive pulmonary disease

• DOI: 10.3760/cma.j.issn.1673-436x.2014.21.005
• Publication Date: 2014-11-05
• Authors: Yuhai Gu; Lina Zhen; Youbang Xie
• Keywords: Conventional treatment; Therapeutic effect

Objective Serum of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor metalloproteinases-1 (TIMP-1) levels moderate severe acute exacerbations chronic obstructive pulmonary disease (AECOPD) patients before after treatment were tested using ELISA to observe the effect montelukast modiumr on serum MMP-9 TIMP-1 levels.Methods Sixty-three cases mild AECOPD selected that randomly divided into 30 as group 33 control group.The given conventional therapy plus sodium (10 mg oral once-daily for 7-14 days).The days.Serum in compared with its changes.Results ①Before treatment,the comparison level between has no significant difference (P ＞0.05).While [(22.02 ± 6.34)μg/L] is higher than [(26.31±8.23) μg/L](P ＜0.05).The [(27.59 7.71) μg/L] [(27.74 7.96) respectively 6.34) μg/L],[(26.31 8.23) ＜0.05).②Serum group(P ＜ 0.05).Though different these two groups [(22.23±5.52) μg/L],[(17.23±8.23) pg/L,respectively](P [(16.34±1.45) μtg/L] [(16.20±2.03) [(22.23 5.52) μg/L,(17.23 2.45) pg/L,respectively 0.05).Conclusions Montelukast sodiumr do have an AECOPD,which seems may alleviate inflammation air flue delay airway remodeling.

Key words: Acute disease; Matrix ; Tissue